Niederle N - Search Results

1

Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia.

Kloke O, Becher R, Niederle N. Kloke O, et al. Among authors: niederle n. Blut. 1987 Nov;55(5):453-8. doi: 10.1007/BF00367463. Blut. 1987. PMID: 3118992

2

Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders.

Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, Seeber S, Niederle N. Wandl UB, et al. Among authors: niederle n. Clin Immunol Immunopathol. 1992 Oct;65(1):70-4. doi: 10.1016/0090-1229(92)90250-r. Clin Immunol Immunopathol. 1992. PMID: 1382910

3

Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia.

Wandl UB, Kloke O, Nagel-Hiemke M, Moritz T, Becher R, Opalka B, Holtkamp W, Bartels H, Seeber S, Niederle N. Wandl UB, et al. Among authors: niederle n. Br J Haematol. 1992 Aug;81(4):516-9. doi: 10.1111/j.1365-2141.1992.tb02984.x. Br J Haematol. 1992. PMID: 1390238

4

Tumor necrosis factor alpha modifies resistance to interferon alpha in vivo: first clinical data.

Moritz T, Kloke O, Nagel-Hiemke M, Kummer G, Wandl UB, Opalka B, Plappert B, Kempeni J, Seeber S, Niederle N. Moritz T, et al. Among authors: niederle n. Cancer Immunol Immunother. 1992;35(5):342-6. doi: 10.1007/BF01741148. Cancer Immunol Immunother. 1992. PMID: 1394338 Free PMC article. Clinical Trial.

5

A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.

Kloke O, Wandl U, Opalka B, Moritz T, Nagel-Hiemke M, Franz T, Becher R, Hirche H, Seeber S, Niederle N. Kloke O, et al. Among authors: niederle n. Eur J Haematol. 1992 Feb;48(2):93-8. doi: 10.1111/j.1600-0609.1992.tb00572.x. Eur J Haematol. 1992. PMID: 1547881 Clinical Trial.

6

Treatment of chronic myelogenous leukemia with different cytokines.

Wandl UB, Opalka B, Kloke O, Nagel-Hiemke M, Moritz T, Niederle N. Wandl UB, et al. Among authors: niederle n. Semin Oncol. 1992 Apr;19(2 Suppl 4):88-94. Semin Oncol. 1992. PMID: 1553580 Clinical Trial.

7

Interferon alfa-2b in acute- and chronic-phase chronic myelogenous leukaemia: initial response and long-term results in 54 patients.

Niederle N, Moritz T, Kloke O, Wandl U, May D, Becher R, Franz T, Opalka B, Schmidt CG. Niederle N, et al. Eur J Cancer. 1991;27 Suppl 4:S7-14. doi: 10.1016/0277-5379(91)90556-s. Eur J Cancer. 1991. PMID: 1799485

8

Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha.

Doberauer C, Mengelkoch B, Kloke O, Wandl U, Niederle N. Doberauer C, et al. Among authors: niederle n. Acta Oncol. 1991;30(5):603-5. doi: 10.3109/02841869109092426. Acta Oncol. 1991. PMID: 1892678

9

Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.

Opalka B, Wandl UB, Becher R, Kloke O, Nagel-Hiemke M, Moritz T, Beer U, Seeber S, Niederle N. Opalka B, et al. Among authors: niederle n. Blood. 1991 Nov 1;78(9):2188-93. Blood. 1991. PMID: 1932740 Free article. Clinical Trial.

10

Breakpoint localization within the M-bcr and clinical course do not correlate in patients with chronic myelogenous leukemia undergoing alfa interferon therapy.

Opalka B, Wandl U, Beer U, Roggenbuck U, Kloke O, Niederle N. Opalka B, et al. Among authors: niederle n. Leukemia. 1991 Jun;5(6):452-6. Leukemia. 1991. PMID: 2056769

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters